drugset / Trial / NCT02728271

Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome

NCT02728271

Phase 0 Terminated 1 enrolled Mounzer Agha
NaSingle-groupOpen-labelTreatment

Summary

Churg-Strauss syndrome is a rare autoimmune inflammatory disease affecting medium- and small-sized blood vessels, causing asthma, abnormalities of the blood, lung diseases, and neuropathy. The main cause of death in these patients is heart attack. Without therapy, the 5-year survival in patients with Churg-Strauss syndrome is 25%. Although with the 5-year survival is increased to 62% with the appropriate therapy, many patients remain refractory to therapy. The long term outcome of these patients remains grim. The aim of this research study is to determine if suppressing the immune system using a combination of high dose chemotherapy, antibodies, and radiation followed by stem cell transplant will abolish the 'bad' immune system and let the patient's body establish a new immune system that does not attack the blood vessels.

Timeline

Start
2016-04
Primary completion
2016-07-22
Completion
2016-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject HPC Unknown 5e+06 cells/kg
Subject antithymocyte globulins Unknown